New Products In Brief
This article was originally published in The Rose Sheet
Executive Summary
Indena’s Hyaluronic Acid Alternative
You may also be interested in...
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
Behavioral Health Company Two Chairs Secures $72M In Equity And Debt Infusion
Two Chairs, which uses algorithms to match the right therapists with patients, secured $72m in investment to expand its business.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.